It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Whole genome sequencing (WGS) provides comprehensive, individualised cancer genomic information. However, routine tumour biopsies are formalin-fixed and paraffin-embedded (FFPE), damaging DNA, historically limiting their use in WGS. Here we analyse FFPE cancer WGS datasets from England’s 100,000 Genomes Project, comparing 578 FFPE samples with 11,014 fresh frozen (FF) samples across multiple tumour types. We use an approach that characterises rather than discards artefacts. We identify three artefactual signatures, including one known (SBS57) and two previously uncharacterised (SBS FFPE, ID FFPE), and develop an “FFPEImpact” score that quantifies sample artefacts. Despite inferior sequencing quality, FFPE-derived data identifies clinically-actionable variants, mutational signatures and permits algorithmic stratification. Matched FF/FFPE validation cohorts shows good concordance while acknowledging SBS, ID and copy-number artefacts. While FF-derived WGS data remains the gold standard, FFPE-samples can be used for WGS if required, using analytical advancements developed here, potentially democratising whole cancer genomics to many.
Formalin fixation is commonly used in tissue storage; however, this process has traditionally limited downstream whole genome sequencing usage. Here, the authors identify artefactual signatures in FFPE-derived sequencing data and demonstrate the preservation of clinical utility, thus enabling FFPE whole genome sequencing when required.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 University of Cambridge, Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge, Early Cancer Institute, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934)
2 University of Cambridge, Precision Breast Cancer Institute, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000 0001 2188 5934); Li Ka Shing Centre, Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
3 Cambridge University Hospitals, Cambridge Cancer Trials Centre, Department of Oncology, Cambridge, UK (GRID:grid.24029.3d) (ISNI:0000 0004 0383 8386)
4 One Canada Square, Genomics England, London, UK (GRID:grid.498322.6)
5 University of Oxford, Department of Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); RIKEN Centre for Integrative Medical Sciences, Yokohama, Japan (GRID:grid.509459.4) (ISNI:0000 0004 0472 0267)
6 Illumina Centre, Illumina Cambridge, Ltd, Cambridge, UK (GRID:grid.434747.7)
7 Li Ka Shing Centre, Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
8 University of Oxford, Department of Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
9 Charterhouse Square, Barts Cancer Institute, Queen Mary University of London, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)
10 University of Cambridge, Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)